- Home
- Companies
- MedChemExpress LLC (MCE)
- Products
- MedChemExpress - Model Ocaratuzumab - ...
MedChemExpress - Model Ocaratuzumab -1169956-08-4
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC)[1][2].MCE products for research use only. We do not sell to patients.
Ocaratuzumab
MCE China：Ocaratuzumab
Brand：MedChemExpress (MCE)
Cat. No.HY-P99308
CAS：1169956-08-4
Synonyms：AME 133v; LY 2469298; Humanized Anti-MS4A1 Recombinant Antibody
Purity：95.00%
Storage：Please store the product under the recommended conditions in the Certificate of Analysis.
Description：Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC).
In Vitro：AME-133v (0.027-20 μg/mL) concentration-dependently inhibits the binding of biotinylated Rituximab to CD20 in SKW6.4 cells[1].
IC50 & Target：Kd: ~100 pM (CD20)[1] In Vitro AME-133v (0.027-20 μg/mL) concentration-dependently inhibits the binding of biotinylated Rituximab to CD20 in SKW6.4 cells[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Ocaratuzumab Related Antibodies
Species：Humanized
Isotype：Human IgG1 kappa
Recommend Isotype Controls：Human IgG1 kappa, Isotype Control
Hot selling product：FL118 | Teduglutide | Brigatinib | Salvianolic acid B | Harringtonine | Ganglioside GM3 | Rifampicin | Sulfo-NHS-SS-Biotin (sodium) | Tetrahydrobiopterin | CART(55-106)(human)
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
References：
[1]. Forero-Torres A, et, al. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012 Mar 1;18(5):1395-403. [Content Brief]
[2]. Cheney CM, et, al. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. MAbs. 2014 May-Jun;6(3):749-55. [Content Brief]
Brand introduction:
• MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world；
• More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas；
• The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects；
• Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services；
• It has a professional experimental center and strict quality control and verification system；
• Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products；
• The biological activity of the products has been verified by the experiments of customers in various countries；
• A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers；
• Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world；
• It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。